<DOC>
	<DOCNO>NCT02457130</DOCNO>
	<brief_summary>Patients type 2 diabetes mellitus ( T2DM ) , high prevalence suboptimal response clopidogrel ( 40 % ) . This impaired response antiplatelet drug consistently associate high risk adverse ischemic outcome . Different strategy suggest overcome variability response clopidogrel improve clinical outcome diabetic patient . One strategy use new P2Y12 inhibitor , ticagrelor , potent consistent platelet inhibitory effect compare clopidogrel . In summary , since patient T2DM continue enhance platelet reactivity despite administration commonly use dual antiplatelet therapy aspirin standard dose clopidogrel , new potent antiplatelet treatment strategy warrant high-risk population . The purpose present study compare platelet inhibitory effect achieve ticagrelor versus clopidogrel , top aspirin therapy , patient type 2 DM stable coronary artery disease .</brief_summary>
	<brief_title>Comparison TIcagrelor Clopidogrel Patients With Coronary Artery diseaSe Type 2 Diabetes Mellitus ( TICS-DM )</brief_title>
	<detailed_description>Despite clinical benefit associate dual therapy consist aspirin clopidogrel , still considerable number patient continue atherothrombotic event . Several study show wide interindividual variability response clopidogrel treatment patient poor response increase risk recurrent ischemic event . In particular , patient type 2 diabetes mellitus ( T2DM ) , high prevalence suboptimal response clopidogrel ( 40 % ) . This impaired response antiplatelet drug consistently associate high risk adverse ischemic outcome . Different strategy suggest overcome variability response clopidogrel improve clinical outcome diabetic patient . One strategy use new P2Y12 inhibitor , ticagrelor , potent consistent platelet inhibitory effect compare clopidogrel . In summary , since patient T2DM continue enhance platelet reactivity despite administration commonly use dual antiplatelet therapy aspirin standard dose clopidogrel , new potent antiplatelet treatment strategy warrant high-risk population . The purpose present study compare platelet inhibitory effect achieve ticagrelor versus clopidogrel , top aspirin therapy , patient type 2 DM stable coronary artery disease ( CAD ) . This multi-center prospective , open-label , two-sequence , two-period , randomize crossover study conduct T2DM patient age 18 75 year know CAD . Subjects randomize 1:1 fashion take ticagrelor ( 180-mg loading dose first day follow 90-mg maintenance dose ) clopidogrel ( 600-mg loading dose first day follow 75-mg daily maintenance dose ) one-week background aspirin therapy ( 100 mg daily ) . After 2-4 week washout period , subject cross-over treatment regimen . The washout period include minimize carryover effect treatment regimen . Patient compliance assess interview pill count . Platelet function test perform follow time-points ( repeat two period treatment ) : baseline , 2 24 hour take load dose assign drug , 1 week initiating assign drug . All statistical comparison platelet function primary secondary endpoint conduct use linear mixed-effect model treatment , sequence , period treatment*period ( treatment period interaction order test carryover effect ) fix effect , subject random effect baseline value correspond platelet function test covariate . A two-tailed p value le 0.05 consider indicate statistically significant difference analysis perform .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Age 18 75 year Type 2 DM accord ADA criterion Angiographically document CAD Chronic treatment ( &gt; 1 month ) aspirin ( 100mg/day ) Known allergy aspirin , clopidogrel , ticagrelor Blood dyscrasia Any recent acute coronary syndrome ( &lt; 30 day ) hemodinamic instability Recent antiplatelet therapy ( &lt; 14 day ) , exception ASA , include : thienopyridines , cilostazol , dipiridamol , glycoprotein IIb/IIIa inhibitor Oral anticoagulation coumarin derivative Concomitant treatment potent CYP3A4 inhibitor ( e.g . ketoconazole , claritromicine , nefazodone , ritonavir , atazanavir ) Any active bleeding Recent history stroke , TIA intracranial bleeding ( &lt; 6 month prior inclusion ) Platelet count &lt; 100x106/microl Severe chronic kidney disease ( creatinine clearance measure CockcroftGault formula &lt; 30ml/min ) Any active neoplasm Baseline ALT &gt; 2.5 time upper limit normality Pregnant childbearing female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>